NWBO has not filed for NDA yet FCB, there is not a chance for CRL. FDA has no review of this outcome, similar to IMUC's. trial there has not been halted, but data will mature and it may be differnt story.
we want to see what happend all these two years of trials, were we better than standard of Care or not and if our PFS was significantly better than SC or not. If better, sky is the limit.
News 
Market Data 
Discover 
AI
